Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655180 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10LMNATSHR | |
| SCHEMBL14003000 | 0.85 | ALDH1A1 (0.42) | ALDH1A1KDM4EHSD17B10LMNATSHR | |
| SCHEMBL2475545 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EHSD17B10POLBGAA | |
| SCHEMBL10091946 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10LMNAMAPT | |
| SCHEMBL30546103 | 0.80 | PBRM1 (0.36) | ALDH1A1KDM4ELMNAMAPK1GAA | |
| SCHEMBL26125017 | 0.80 | KDM4E (0.35) | ALDH1A1KDM4EMAPTHTTGAA | |
| SCHEMBL26124805 | 0.80 | MAOB (0.38) | — | |
| SCHEMBL2530842 | 0.80 | PBRM1 (0.36) | ALDH1A1KDM4ELMNAMAPK1GAA | |
| SCHEMBL26124161 | 0.80 | CYP19A1 (0.43) | ALDH1A1KDM4EHSD17B10LMNATSHR | |
| SCHEMBL26127662 | 0.78 | MAOB (0.41) | ALDH1A1KDM4EMAPTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117186045-A | Isobenzofuran-1 (3H) -ketone TREK-1 inhibitor, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-12-08 | — | — | CN | claimed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | claimed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | claimed |
| US-12612425-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2026-04-28 | — | — | US | disclosed |
| WO-2026048960-A1 | METHOD FOR PRODUCING OLAPARIB PRECURSOR AND METHOD FOR PRODUCING OLAPARIB | アルプス薬品工業株式会社 | 2026-03-05 | — | — | WO | disclosed |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | ATLASMEDX, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240351989-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | ALIVUS LIFE SCIENCES LIMITED (IN) | 2024-10-24 | — | — | US | disclosed |
| EP-4384501-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | Glenmark Life Sciences Limited (IN) | 2024-06-19 | — | — | EP | disclosed |
| CN-113811333-B | Compounds targeting anti-cancer nuclear hormone receptors | 诺维逊生物股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4289813-A2 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289813-A2 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20060149059-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-20060142293-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20060063767-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LTD (GB) | 2006-03-23 | — | — | US | disclosed |
| WO-2006021801-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021801-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| US-20050059663-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| US-20040023968-A1 | Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | ALDH1A1 1599/4885KDM4E 3328/4885HSD17B10 106/4885 |
| US-20050059663-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | ALDH1A1 1678/4885KDM4E 3377/4885HSD17B10 109/4885 |
| US-20060142293-A1 | Phthalazinone derivatives | CBR1, CBR3, PARP2 | ALDH1A1 466/4885KDM4E 3266/4885HSD17B10 498/4885 |
| US-20040023968-A1 | Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors | PARP1, PARP2, PARP15 | ALDH1A1 345/4885KDM4E 707/4885HSD17B10 147/4885 |
| US-20240351989-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | PARP1, PARP2, PARP4 | ALDH1A1 1541/4885KDM4E 1213/4885HSD17B10 1601/4885 |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | PARP1, PARP11, PARP3 | ALDH1A1 208/4885KDM4E 2852/4885HSD17B10 230/4885 |
| US-20060149059-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | ALDH1A1 1599/4885KDM4E 3328/4885HSD17B10 106/4885 |
| US-20060063767-A1 | Phthalazinone derivatives | PARP1, PARP2, NR0B1 | ALDH1A1 1422/4885KDM4E 2639/4885HSD17B10 242/4885 |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | ALDH1A1 1089/4885KDM4E 2587/4885HSD17B10 1530/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | ALDH1A1 1599/4885KDM4E 3328/4885HSD17B10 106/4885 |
| US-12612425-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | PARP1, PARP2, PARP11 | ALDH1A1 732/4885KDM4E 2998/4885HSD17B10 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.